Results 231 to 240 of about 145,969 (308)
Abstract Aims Heart failure with preserved ejection fraction (HFpEF) continues to be an increasingly common health problem associated with a high mortality rate. Elevated levels of Growth differentiation factor‐15 (GDF15) and N‐terminal pro‐brain natriuretic peptide (NT‐proBNP) are reportedly associated with poor clinical outcomes in a broad range of ...
Yoichiro Otaki +11 more
wiley +1 more source
High-Density Lipoproteins (HDLs) contribute to limiting acute tissue damage: proof of concept in a model of mercury-induced nephrotoxicity. [PDF]
Gómez-Pineda D +13 more
europepmc +1 more source
Abstract Background Arterial stiffness is a crucial factor in determining an increase in systolic blood pressure and pulse pressure and can also predict the development of cardiovascular disease (CVD). The purpose of this study was to examine the relationship between arterial stiffness and future CVD.
Susan Darroudi +10 more
wiley +1 more source
From lipoprotein metabolism to blood clotting: Highlights of the 2025 Fredrickson lipid research conference. [PDF]
Smith AN +15 more
europepmc +1 more source
Abstract Background There are limited data on the efficacy of smartphone‐based personal health records (PHRs) in patients with cardiovascular disease. This study aimed to examine the processes, outcomes and challenges associated with the implementation of integrated PHRs in patients with heart failure (HF) or coronary artery disease (CAD). Methods This
Kotaro Nochioka +16 more
wiley +1 more source
Beyond Fasting Lipids: Nutritional and Clinical Perspectives on Postprandial Triglycerides. [PDF]
Patru O +9 more
europepmc +1 more source
Abstract Heart failure with preserved ejection fraction (HFpEF) is characterized by a lack of a specific targeted treatment and a complex, partially unexplored pathophysiology. Common comorbidities associated with HFpEF are hypertension, atrial fibrillation, obesity and diabetes.
Giorgia D'Italia +2 more
wiley +1 more source
Nonfasting lipid testing: all the good reasons to do it, and potential physician and patient behaviors preventing its implementation. [PDF]
Xiang P, Hanjani K, Francis GA.
europepmc +1 more source
Prediction of LVEF improvement in patients with HFrEF and HFmrEF following treatment with Sacubitril/Valsartan. Workflow of this study investigating the functional capacity improvement in response to Sacubitrail/Valsartsan in a real‐world scenario of heart failure treatment.
Florian Appenzeller +8 more
wiley +1 more source

